Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:379
  • Home
  • Print this page
  • Email this page
SHORT COMMUNICATION
Year : 2022  |  Volume : 7  |  Issue : 2  |  Page : 209-212

Role of double-filtration plasmapheresis in ABO- and human leukocyte antigen-incompatible kidney transplant


1 Department of Nephrology and Renal Transplant, Sarvodaya Hospital and Research Centre, Faridabad, Haryana, India
2 Transfusion Medicine and Blood Centre, Sarvodaya Hospital and Research Centre, Faridabad, Haryana, India
3 Department of Urology and Renal Transplant, Sarvodaya Hospital and Research Centre, Faridabad, Haryana, India
4 Department of Pathology, Sarvodaya Hospital and Research Centre, Faridabad, Haryana, India
5 Department of Medical Administration, Sarvodaya Hospital and Research Centre, Faridabad, Haryana, India

Correspondence Address:
Saikat Mandal
Transfusion Medicine and Blood Centre, Sarvodaya Hospital and Research Centre, Faridabad, Haryana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/gjtm.gjtm_7_22

Rights and Permissions

Kidney transplant has significantly improved the quality of life in end-stage renal disease patients compared to maintenance hemodialysis. Recipients can receive a living-donor or a deceased-donor kidney transplant. However, the presence of donor specific anti human leukocyte antigen (HLA) antibodies or anti A or B antibodies in the recipient makes the transplant incompatible and provokes to cause hyperacute, acute, or chronic rejection. Desensitization which is usually applied before to reduce incompatibility can be achieved by apheresis and preventing donor-specific antibody resynthesis by targeting both T and B cells. Here, we present two such cases transplanted successfully by desensitizing with double-filtration plasmapheresis (DFPP). Case 1 which was a female with high-titer anti-HLA antibody was managed with rituximab, 4 sessions of DFPP, antithymocyte globulin, and posttransplant Tacrolimus (Tac). Case 2 who had both high-titer anti-HLA and anti-A (IgG 1:256) antibody was managed with rituximab, 3 sessions of DFPP, and posttransplant Tac. In both cases, perioperative complications due to DFPP such as bleeding, thrombocytopenia, hypotension, and need of transfusion was minimal. These cases point toward successful application of DFPP in desensitization protocol, leading to successful HLA antibody-incompatible and ABO-incompatible renal transplant with minimal adverse incident and cost.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed216    
    Printed4    
    Emailed0    
    PDF Downloaded15    
    Comments [Add]    

Recommend this journal